Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy

Phase 2

Terminated

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer

Interventions: Drug: cediranib maleate
Drug: docetaxel
Drug: prednisone
Other: laboratory biomarker analysis

First Posted Date: 2007-09-10

Last Posted Date: 2018-08-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 57

Registration Number: NCT00527124

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Wayne State University, Detroit, Michigan, United States

and more 1 locations

LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive

Phase 4

Completed

Conditions: Acute Lymphoblastic Leukemia

First Posted Date: 2007-09-10

Last Posted Date: 2010-01-05

Lead Sponsor: PETHEMA Foundation

Target Recruit Count: 100

Registration Number: NCT00526305

Locations: 🇪🇸
Hospital General de Segovia, Segovia, Spain
🇪🇸
Hospital Universitario de Canarias, Tenerife, Spain
🇪🇸
H.U. Virgen del Rocio, Sevilla, Spain

and more 46 locations

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erythropoietin
Drug: Cyclosporin A
Drug: G-CSF
Drug: Prednisone

First Posted Date: 2007-08-24

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00520468

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

An Open-Label Study of YM155 + Docetaxel in Subjects With Advanced Hormone Refractory Prostate Cancer and Other Solid Tumors

Phase 1

Completed

Conditions: Prostate Cancer
Tumors

Interventions: Drug: YM 155
Drug: Docetaxel
Drug: Prednisone

First Posted Date: 2007-08-09

Last Posted Date: 2015-08-13

Lead Sponsor: Astellas Pharma Inc

Target Recruit Count: 32

Registration Number: NCT00514267

Combination Chemotherapy and Denileukin Diftitox in Treating Patients With Newly Diagnosed T-Cell Non-Hodgkin Lymphoma

Not Applicable

Withdrawn

Conditions: Lymphoma

First Posted Date: 2007-08-08

Last Posted Date: 2016-12-15

Lead Sponsor: University of Miami

Registration Number: NCT00513188

Locations: 🇺🇸
University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami, Florida, United States

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: prednisone
Drug: vinblastine
Drug: doxorubicin
Drug: gemcitabine

First Posted Date: 2007-08-08

Last Posted Date: 2015-12-03

Lead Sponsor: University of Cologne

Registration Number: NCT00512980

Locations: 🇩🇪
University of Cologne, Cologne, Germany

Evaluation of Birdshot Retine Choroidopathy Treatment by Either Steroid or Interferon alpha2a

Phase 2

Completed

Conditions: Birdshot Chorioretinopathy
Cystoid Macular Edema
Transient Partial Visual Loss

Interventions: Drug: interferon alpha 2a
Drug: prednisone

First Posted Date: 2007-07-27

Last Posted Date: 2013-01-23

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 58

Registration Number: NCT00508040

Locations: 🇫🇷
Hopital La Pitie Salpetriere, Paris, France

Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Bortezomib
Drug: Dexamethasone
Drug: Melphalan
Drug: Thalidomide
Drug: Prednisone

First Posted Date: 2007-07-26

Last Posted Date: 2014-05-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 502

Registration Number: NCT00507416

Locations: 🇺🇸
Hematology Oncology Consultants Inc., Columbus, Ohio, United States
🇺🇸
S. Florida Oncology/ Hematology, West Palm Beach, Florida, United States
🇺🇸
Hematology-Oncology Clinic, Baton Rouge, Louisiana, United States

and more 219 locations